RESUMO
CONTEXT: In 2012, The North American Cystic Fibrosis Foundation (NACFF) published new guidelines for the treatment of vitamin D deficiency in individuals with cystic fibrosis (CF). OBJECTIVE: The objectives of our study were to assess the efficacy of these guidelines, and to test the effect of increasing vitamin D dosage on pulmonary function and exacerbations. DESIGN: Pulmonary function tests and serum concentrations of 25-hydroxyvitamin D [25(OH)D] were measured 1 year before increasing vitamin D dosage according to the guidelines and at least 1 year later. In addition, days of hospitalization and pulmonary exacerbations were counted and an average per year (average number of days of hospitalization and average number of pulmonary exacerbations [PEA], respectively) was calculated. SETTING AND PARTICIPANTS: A total of 90 patients from The Cystic Fibrosis Clinic at Hadassah Mount-Scopus Hospital, Jerusalem, Israel. RESULTS: The mean serum concentration of vitamin D increased significantly from 20.97âng/mL (52.34ânmol/L) at baseline to 25.41âng/mL (63.42ânmol/L) at the end of follow-up (Pâ<â0.001). The number of PEA decreased significantly from 2.79â±â3.96 to 2.15â±â2.91 (Pâ=â0.007). The change in vitamin D levels was correlated with a decrease in PEA (correlation coefficientâ=â-0.318, Pâ=â0.002). CONCLUSIONS: The NACFF guidelines for management of vitamin D deficiency improve vitamin D levels in patients with CF but did not reach the normal values in most patients. The increase in vitamin D serum levels was, however, associated with a decrease in number of pulmonary exacerbations.
Assuntos
Fibrose Cística/sangue , Suplementos Nutricionais , Progressão da Doença , Deficiência de Vitamina D/terapia , Vitamina D/análogos & derivados , Adolescente , Criança , Pré-Escolar , Fibrose Cística/complicações , Fibrose Cística/fisiopatologia , Suplementos Nutricionais/normas , Feminino , Seguimentos , Humanos , Lactente , Tempo de Internação/estatística & dados numéricos , Pulmão/fisiopatologia , Masculino , Guias de Prática Clínica como Assunto , Testes de Função Respiratória , Resultado do Tratamento , Vitamina D/administração & dosagem , Vitamina D/sangue , Vitamina D/normas , Deficiência de Vitamina D/etiologia , Deficiência de Vitamina D/fisiopatologia , Vitaminas/administração & dosagem , Vitaminas/normasRESUMO
We report physiotherapy management of two patients with severe cystic fibrosis (CF) lung disease and upper limb deep vein thrombosis (DVT). These patients were admitted due to a pulmonary exacerbation. Following peripherally inserted central catheters, they were diagnosed with an upper limb DVT. Due to their underlying lung disease, physiotherapy was mandatory for improvement. However, the DVT and anticoagulation treatment raised concerns for pulmonary emboli and hemoptysis. A framework for physiotherapy management in these patients, using a set of precautions and restrictions to maintain airway clearance while minimizing the risk for pulmonary emboli and hemoptysis, was established. Using this set of instructions, the patients experienced no major adverse events while maintaining sufficient airway clearance to allow respiratory improvement. These precautions were continued until the upper limb DVTs were resolved. To our knowledge, there are currently no guidelines or expert opinions available. Therefore, this framework can help guide physiotherapy management.
Assuntos
Fibrose Cística , Embolia Pulmonar , Trombose Venosa , Fibrose Cística/complicações , Fibrose Cística/terapia , Hemoptise , Humanos , Modalidades de Fisioterapia , Fatores de Risco , Extremidade Superior , Trombose Venosa/complicações , Trombose Venosa/terapiaRESUMO
BACKGROUND: Consistently abnormal glucose levels on oral glucose tolerance test (OGTT) are the most effective screening tool for cystic fibrosis-related diabetes (CFRD). However, some cystic fibrosis (CF) patients demonstrate abnormal glucose profiles not reaching levels required for CFRD diagnosis and are, therefore, left untreated. Since CFRD is associated with disease deterioration, early diagnosis and treatment are desirable. AIM: To explore the association between the area under the curve of glucose (G-AUC) obtained during a five-point 2-h standard OGTT and CF disease severity parameters. METHODS: All CF patients referred for an annual routine OGTT at the Hadassah CF Center between 2002 and 2018, were included. Disease severity parameters were correlated with the G-AUC. RESULTS: Two hundred forty-two OGTTs were performed in 81 patients (mean age 19.7 ± 9.0 years); 54% were normal, 14% showed impaired glucose tolerance (IGT), 5% had values in the indeterminate range (INDET), 11% had both IGT and INDET and 16% were diagnosed with CFRD. A gradual increase in mean G-AUC was observed among the groups. In multivariate regression models, G-AUC ≥ 295 mg h/dl was independently associated with an increased number of pulmonary exacerbations (PEx). Not all the patients having this value met the CFRD definition. CONCLUSION: Patients who do not fulfill the criteria for CFRD may have abnormal glucose metabolism identifiable by abnormally high G-AUC values, which may be associated with more PEx. The potential advantage of treating these patients with insulin and the subsequent reduction in PEx needs further investigation.
Assuntos
Fibrose Cística , Diabetes Mellitus , Intolerância à Glucose , Adolescente , Adulto , Glicemia/metabolismo , Criança , Fibrose Cística/complicações , Fibrose Cística/diagnóstico , Diabetes Mellitus/diagnóstico , Glucose , Intolerância à Glucose/complicações , Intolerância à Glucose/diagnóstico , Teste de Tolerância a Glucose , Humanos , Insulina , Adulto JovemRESUMO
OBJECTIVES: Treatment with pancreatic enzymes fails to completely correct malabsorption and gastrointestinal symptoms in patients with cystic fibrosis (CF). The aim of the present study was to examine the small intestine of patients with CF without overt evidence of gastrointestinal disease using capsule endoscopy (CE). METHODS: Patients with CF received the agile patency capsule and, depending on the result of that procedure, then underwent standard CE using the PillCam SB capsule (Given Imaging, Yokneam, Israel). A stool specimen was taken on the same day as the CE for determination of the calprotectin level. RESULTS: Forty-two patients with CF ages 10 to 36 years were included; 29 had pancreatic insufficiency. One patient failed to excrete the patency capsule after 36 hours and was withdrawn from the study. Pulmonary function was mild to moderate with FEV1 68.5% +/- 16% predicted. Review of the CE videos showed that most of the patients had varying degrees of diffuse areas of inflammatory findings in the small bowel including edema, erythema, mucosal breaks, and frank ulcerations. There were no adverse events. Fecal calprotectin levels were markedly high in patients with pancreatic insufficiency, 258 microg/g (normal <50). CONCLUSIONS: Small bowel mucosal pathology may be detected using CE in most of the patients with CF. The high fecal calprotectin levels found are suggestive of mucosal inflammation, which may correlate with the CE findings. Additional study is required to examine the possible relation of these mucosal lesions, which may be part of a newly identified enteropathy associated with CF, with persistent intestinal malabsorption in many of these patients.
Assuntos
Fibrose Cística/patologia , Insuficiência Pancreática Exócrina/epidemiologia , Inflamação/patologia , Mucosa Intestinal/patologia , Intestino Delgado/patologia , Complexo Antígeno L1 Leucocitário/análise , Mucosite/patologia , Adolescente , Adulto , Endoscopia por Cápsula/métodos , Criança , Fibrose Cística/complicações , Fibrose Cística/fisiopatologia , Edema/etiologia , Eritema/etiologia , Insuficiência Pancreática Exócrina/etiologia , Fezes/química , Feminino , Volume Expiratório Forçado , Humanos , Incidência , Inflamação/etiologia , Pulmão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Mucosite/etiologia , Úlcera/etiologia , Adulto JovemRESUMO
BACKGROUND: In about 10% of patients worldwide and more than 50% of patients in Israel, cystic fibrosis results from nonsense mutations (premature stop codons) in the messenger RNA (mRNA) for the cystic fibrosis transmembrane conductance regulator (CFTR). PTC124 is an orally bioavailable small molecule that is designed to induce ribosomes to selectively read through premature stop codons during mRNA translation, to produce functional CFTR. METHODS: This phase II prospective trial recruited adults with cystic fibrosis who had at least one nonsense mutation in the CFTR gene. Patients were assessed in two 28-day cycles. During the first cycle, patients received PTC124 at 16 mg/kg per day in three doses every day for 14 days, followed by 14 days without treatment; in the second cycle, patients received 40 mg/kg of PTC124 in three doses every day for 14 days, followed by 14 days without treatment. The primary outcome had three components: change in CFTR-mediated total chloride transport; proportion of patients who responded to treatment; and normalisation of chloride transport, as assessed by transepithelial nasal potential difference (PD) at baseline, at the end of each 14-day treatment course, and after 14 days without treatment. The trial was registered with who.int/ictrp, and with clinicaltrials.gov, number NCT00237380. FINDINGS: Transepithelial nasal PD was evaluated in 23 patients in the first cycle and in 21 patients in the second cycle. Mean total chloride transport increased in the first treatment phase, with a change of -7.1 (SD 7.0) mV (p<0.0001), and in the second, with a change of -3.7 (SD 7.3) mV (p=0.032). We recorded a response in total chloride transport (defined as a change in nasal PD of -5 mV or more) in 16 of the 23 patients in the first cycle's treatment phase (p<0.0001) and in eight of the 21 patients in the second cycle (p<0.0001). Total chloride transport entered the normal range for 13 of 23 patients in the first cycle's treatment phase (p=0.0003) and for nine of 21 in the second cycle (p=0.02). Two patients given PTC124 had constipation without intestinal obstruction, and four had mild dysuria. No drug-related serious adverse events were recorded. INTERPRETATION: In patients with cystic fibrosis who have a premature stop codon in the CFTR gene, oral administration of PTC124 to suppress nonsense mutations reduces the epithelial electrophysiological abnormalities caused by CFTR dysfunction.
Assuntos
Códon de Terminação/efeitos dos fármacos , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Fibrose Cística/tratamento farmacológico , Fibrose Cística/genética , Oxidiazóis/uso terapêutico , Adolescente , Adulto , Cloretos/metabolismo , Códon sem Sentido/efeitos dos fármacos , Códon sem Sentido/genética , Regulador de Condutância Transmembrana em Fibrose Cística/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oxidiazóis/efeitos adversos , Oxidiazóis/farmacologia , Resultado do TratamentoAssuntos
Antibacterianos/administração & dosagem , Fibrose Cística/tratamento farmacológico , Dessensibilização Imunológica , Hipersensibilidade a Drogas/complicações , beta-Lactamas/administração & dosagem , Administração Intravenosa , Adolescente , Adulto , Fibrose Cística/complicações , Esquema de Medicação , Hipersensibilidade a Drogas/terapia , Feminino , Humanos , Masculino , Adulto JovemRESUMO
BACKGROUND: Clinical trials are all based on the assumption that patients are adherent to the study protocol. Many reports indicate that general adherence of patients with CF to their daily routine therapies is poor. However, no data exists on adherence to study drug regimens. METHODS: All clinical trials carried out at the Hadassah CF Center from 2008 to 2013 were reviewed. Actual adherence as determined by counted drugs was analyzed according to drug administration mode, study lengths and number of study visits. A subset of patients answered a two-part questionnaire covering study specific and general treatment specific issues. RESULTS: Eight studies including 118 patients, with patient numbers varying between 4 and 32 per trial were analyzed. For 7/8 studies mean adherence was between 78% to 100%. Comparison with administration mode showed that adherence decreased substantially if the drugs were not provided as "ready to be used" (63%). Study length influenced adherence, the longer the study the poorer the adherence (82% trial beginning, 44% post 36 months [two combined studies with identical drug]). A substantial decrease was noted over Holiday periods and during the summer vacation months. No correlation was found between number of study visits and adherence to study drug. CONCLUSION: Adherence to study drug is generally higher than that for regular treatment. Study length, mode of administration, and timing according to Holidays and vacations adversely affect adherence.
Assuntos
Ensaios Clínicos como Assunto , Fibrose Cística/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Administração por Inalação , Administração Oral , Férias e Feriados/estatística & dados numéricos , Humanos , Projetos Piloto , Inquéritos e QuestionáriosRESUMO
OBJECTIVE: To investigate the effect of treatment with ivacaftor on insulin secretion in patients with cystic fibrosis (CF) (ΔF508\S549R) having CFRD/impaired insulin secretion. METHODS: A standard OGTT was performed before and after 16weeks of treatment with ivacaftor in 2 sibling patients with CF carrying the S549R gating mutation. The area under the curve (AUC) for glucose and insulin was calculated using the trapezoidal estimation. RESULTS: Before treatment, the OGTT of case 1 showed indeterminate glycemia; the OGTT of case 2 indicated CFRD. After ivacaftor treatment the OGTT demonstrated improved insulin secretion pattern mainly by increased first phase early insulin secretion, resulting in reduction of the AUC of glucose in both cases. CONCLUSIONS: The treatment with ivacaftor in patients with CF carrying gating mutation can ameliorate impaired insulin secretion. Further studies and larger cohorts are needed to evaluate the impact of ivacaftor on insulin secretion in patients with CF carrying gating or other mutations.
Assuntos
Aminofenóis , Fibrose Cística/tratamento farmacológico , Insulina/metabolismo , Quinolonas , Aminofenóis/administração & dosagem , Aminofenóis/farmacocinética , Glicemia/análise , Agonistas dos Canais de Cloreto/administração & dosagem , Agonistas dos Canais de Cloreto/farmacocinética , Fibrose Cística/genética , Fibrose Cística/metabolismo , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Feminino , Humanos , Secreção de Insulina , Masculino , Mutação , Quinolonas/administração & dosagem , Quinolonas/farmacocinética , Irmãos , Resultado do Tratamento , Adulto JovemRESUMO
Eradication of Pseudomonas aeruginosa (PA) is critical in cystic fibrosis (CF) patients. OBJECTIVES: To determine eradication success rate of newly acquired PA and to identify characteristics associated with eradication failure. METHODS: In an observational study, data from patients with newly acquired PA infection from 2007 to 2013 were collected. Clinical variables were compared in patients with and without successful eradication for ≥1year. RESULTS: Of 183 patients out of 740 (25%) from 7 CF Centers that had newly acquired PA, eradication succeeded in 72%. Patients with the highest risk of failure had multi-resistant PA, fewer sputum cultures taken, were older, and were diagnosed at a later age. The risk of eradication failure increased by 1.3% with each year of delayed CF diagnosis; successful eradication increased by 17% with each additional sputum culture taken. CONCLUSIONS: Delayed detection of PA infection leading to delayed treatment and growth of multi-resistant organisms is associated with eradication failure.
Assuntos
Antibacterianos , Fibrose Cística , Controle de Infecções , Infecções por Pseudomonas , Pseudomonas aeruginosa , Adolescente , Adulto , Antibacterianos/classificação , Antibacterianos/uso terapêutico , Criança , Fibrose Cística/complicações , Fibrose Cística/epidemiologia , Fibrose Cística/microbiologia , Fibrose Cística/terapia , Farmacorresistência Bacteriana Múltipla , Feminino , Humanos , Lactente , Controle de Infecções/métodos , Controle de Infecções/estatística & dados numéricos , Israel/epidemiologia , Masculino , Conduta do Tratamento Medicamentoso , Pessoa de Meia-Idade , Avaliação de Processos e Resultados em Cuidados de Saúde , Infecções por Pseudomonas/diagnóstico , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/epidemiologia , Infecções por Pseudomonas/etiologia , Pseudomonas aeruginosa/efeitos dos fármacos , Pseudomonas aeruginosa/isolamento & purificação , Pseudomonas aeruginosa/patogenicidadeRESUMO
BACKGROUND: Airway inflammation plays a critical role in the progression of cystic fibrosis (CF) lung disease, and in the destruction of airways and lung parenchyma. Current methods to assess CF lung disease (BAL, spirometry, and high-resolution CT scanning), do not always accurately reflect actual disease states. Fluorodeoxyglucose (FDG)-PET scanning has been used previously to image infection and inflammation. In this study, we assessed the use of (18)F-FDG PET/CT scanning to evaluate and monitor lung inflammation and/or infection in patients with CF. METHODS: PET/CT scans were performed in 20 patients with CF (age range, 14 to 54 years); 7 of 20 patients underwent repeat PET/CT scans during and after acute exacerbations. The results were compared with clinical information and with images from eight control subjects with no known lung disease. RESULTS: Foci of enhanced activity were observed on FDG-PET scans of patients with CF but not those of control subjects. Higher focal activity (standardized uptake value, > 3.0) was seen during disease exacerbation and infection. Coregistered CT scan images assisted in the localization of PET foci and showed corresponding CT scan findings, with many additional findings on CT scans that were not seen on PET scans. Foci seen on high-intensity PET scans during exacerbations disappeared after antibiotic therapy and the resolution of exacerbation, while corresponding CT scan findings remained unchanged. CONCLUSIONS: PET/CT imaging demonstrated the presence of foci of enhanced uptake that may reflect active focal infectious or inflammatory processes in the lungs. These foci can be cleared with antibiotic therapy. Further studies are needed to validate these results and to determine whether FDG-PET/CT scanning can predict the nature/severity of disease in patients with CF.
Assuntos
Fibrose Cística/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Adolescente , Adulto , Fibrose Cística/fisiopatologia , Progressão da Doença , Fluordesoxiglucose F18 , Volume Expiratório Forçado , Humanos , Pessoa de Meia-Idade , Cintilografia , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Adulto JovemRESUMO
BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) in patients with CF is associated with frequent exacerbations and deterioration of lung function. Oral corticosteroids are standard therapy for ABPA and are associated with severe side effects. Monthly pulses of high-dose intravenous methylprednisolone (HDIVPM) are an effective therapy for autoimmune diseases with fewer side effects compared to oral prednisone, implicating its use for patients with CF who suffer from ABPA. METHODS: 9 patients with CF and ABPA (4 male, 5 female, ages 7-36 years) received HDIVPM (10-15 mg/kg/d), for 3 days per month, and itraconazole, until clinical and laboratory resolution of ABPA. RESULTS: All patients showed clinical and laboratory improvement (FEV(1) increase, serum IgE levels and total eosinophil counts decrease) and treatment was discontinued after 6-10 pulses. Adverse effects were minor and disappeared shortly after each IV pulse therapy. CONCLUSION: High-dose IV-pulse methylprednisolone is an effective treatment for ABPA in CF with minor side effects.